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Abstract
Background Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary tumor of the liver. While surgery remains the
cornerstone of therapy, long-term survival following curative-intent resection is generally poor. The aim of the current study was
to define the incidence of actual long-term survivors, as well as identify clinicopathological factors associated with long-term
survival.
Methods Patients who underwent a curative-intent liver resection for ICC between 1990 and 2015 were identified using a multi-
institutional database. Overall, 679 patients were alive with ≥ 5 years of follow-up or had died during follow-up. Prognostic
factors among patients who were long-term survivors (LT) (overall survival (OS) ≥ 5) were compared with patients who were not
non-long-term survivors (non-LT) (OS < 5).
Results Among the 1154 patients who underwent liver resection for ICC, 5- and 10-year OS were 39.6 and 20.3% while the
actual LT survival rate was 13.3%. After excluding 475 patients who survived < 5 years, as well as patients were alive yet had <
5 years of follow-up, 153 patients (22.5%) who survived ≥ 5 years were included in the LT group, while 526 patients (77.5%)
who died < 5 years from the date of surgery were included in the non-LT group. Factors associated with not surviving to 5 years
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included perineural invasion (OR 4.78, 95% CI, 1.92–11.8; p = 0.001), intrahepatic metastasis (OR 3.75, 95% CI, 0.85–16.6,
p = 0.082), satellite lesions (OR 2.12, 95% CI, 1.15–3.90, p = 0.016), N1 status (OR 4.64, 95% CI, 1.77–12.2; p = 0.002), ICC >
5 cm (OR 2.40, 95%CI, 1.54–3.74, p < 0.001), and direct invasion of an adjacent organ (OR 3.98, 95%CI, 1.18–13.4, p = 0.026).
However, a subset of patients (< 10%) who had these pathological characteristics were LT.
Conclusion While ICC is generally associated with a poor prognosis, some patients will be LT. In fact, even a subset of patients
with traditional adverse prognostic factors survived long term.
Keywords Intrahepatic . Cholangiocarcinoma . Long-term .
Survival
Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary liver cancer.1–6 Long-term survival of pa-
tients with unresectable ICC is dismal, with only 5–10% of
patients alive 5 years from the time of diagnosis.7 While sur-
gery remains the only hope for long-term cure for patients
with resectable disease, 5-year overall survival (OS) remains
poor even after hepatic resection (5-year OS, 25–30%). While
several clinicopathological variables have been associated
with prognosis including Cancer Antigen (CA) 19-9, tumor
number and size, lymph node status, margin status, and vas-
cular invasion, the incidence of long-term survivors after
curative-intent surgery remains poorly defined. Traditionally,
the American Joint Committee on Cancer (AJCC) staging
manual has been the main means of stratifying patients with
regard to prognosis8; however, new prognostic tools have also
been accepted and utilized.9 In particular, several studies have
reported on nomograms based on patient and tumor-specific
factors, as well as the impact of perioperative complications
on long-term prognosis for patients with ICC undergoing
surgery.10–18
Following resection of abdominal malignancies, most stud-
ies have examined short-term survival, while fewer studies
have reported data specifically defining long-term survivors.19
In one study of 618 patients who underwent resection for
pancreatic adenocarcinoma, the authors reported an actual 5-
year survival of only 12% following resection.20 AJCC stage
and negative surgical margins were predictive of long-term
survival, while patient age, gender, and tumor location were
not associated with actual 5-year survival. In a separate study,
Zheng et al. reported on a large Western series of actual 10-
year survivors following resection of hepatocellular carcino-
ma (HCC) and noted that surgical margin status was the main
factor associated with long-term survival.21 Despite these re-
ports, no previous study has focused on actual long-term sur-
vivors following resection of ICC. As such, the objective of
the current study was to define the incidence of actual long-
term survivors following curative-intent resection of ICC
using a large, international, multi-center cohort of patients.
In addition, we sought to characterize the impact of
clinicopathological factors on the likelihood of patients to sur-
vive long-term after surgical resection of ICC.
Materials and Methods
Patient Demographic and Clinical Data
Patients who underwent a liver resection for histologically
confirmed ICC between 1990 and 2015 were identified from
amulti-institutional database including 14major hepatobiliary
centers in the USA, Europe, Australia, and Asia (Johns
Hopkins Hospital, Baltimore, MD, n = 89, 7.7%; Stanford
University, Stanford, CA, n = 45, 3.9%; University of
Virginia, Charlottesville, VA, n = 22, 1.9%; Emory
University, Atlanta, GA, n = 72, 6.2%; Fundeni Clinical
Institute of Digestive Disease, Bucharest, Romania, n = 103,
8.9%; Curry Cabral Hospital, Lisbon, Portugal, n = 48, 4.2%;
Ospedale San Raffaele, Milan, Italy, n = 88, 7.6%; Royal
Prince Alfred Hospital, University of Sydney, Sydney,
Australia, n = 38, 3.3%; Eastern Hepatobiliary Surgery
Hospital, Shanghai, China, n = 312, 27.0%; Beaujon
Hospital, Clichy, France, n = 76, 6.6%; University of
Ottawa, Ottawa, Ontario, Canada, n = 26, 2.3%; Erasmus
University Medical Centre, Rotterdam, Netherlands, n = 51,
4.4%; Yokohama City University School of Medicine,
Yokohama, Japan, n = 79, 6.9%; University of Verona,
School of Medicine, Verona, Italy, n = 105, 9.1%). Only pa-
tients who underwent curative intent surgery for non-
metastatic ICC were included, while patients who underwent
a palliative operation were excluded. In addition, patients who
underwent only ablation or intra-arterial therapy (IAT) were
excluded. The Institutional Review Board of each institution
approved the study.
Standard patient demographic, clinicopathologic, tumor-
specific, treatment-related data were collected, as previously
reported.18 Demographic and clinicopathologic data on age,
gender, American Society of Anesthesiologists (ASA) classi-
fication, presence of cirrhosis, HBVor HCV infections, serum
level of carcinoembryonic antigen (CEA), and CA 19-9 were
collected. Treatment-related data included receipt of neoadju-
vant chemotherapy, type of surgery, and receipt of adjuvant
treatments. Of note, resection margin status was classified as
microscopically negative (R0) or microscopically positive
(R1). Patients who underwent non-radical resection
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(macroscopically residual disease (R2)), as well as patients
who underwent palliative surgery or received only non- sur-
gical treatments (ablation or intra-arterial therapies) were ex-
cluded. Tumor-specific characteristics included tumor size
and number, presence of intrahepatic metastasis (multiple he-
patic lesions in separate segments) or satellite lesions (domi-
nant mass with nodules in same segment),22 liver capsule
involvement, vascular/perineural/biliary invasion, and direct
invasion of contiguous organs. Data on histological grade,
morphological type, number of achieved, and metastatic
lymph nodes were also collected. Tumor and lymph node
stages were categorized according to the 8th edition of the
AJCC.8
For the purpose of the study, patients who were alive yet
whose follow-up time was less than 5 years were excluded.
The analytic cohort was categorized into patients who sur-
vived at least 5 years after surgery (i.e., long-term survival
group (LT)) vs. patients who died within 5 years from the date
of surgery (i.e., non-long term survival group (non-LT)).
Statistical Analysis
Continuous variables were summarized as medians with inter-
quartile ranges (IQR) while categorical variables were report-
ed as whole numbers and percentages. Overall survival (OS)
was defined as the time interval between the date of surgery
and the date of death. Time was censored at the date of last
follow-up for living patients. OS estimates were calculated
using the Kaplan-Meier method. Logistic regression models
were used to evaluate associations between clinicopathologi-
cal variables and long-term survival. The coefficients from the
logistic regression models were subsequently reported as odds
ratios (OR) with corresponding 95% confidence intervals
(CI). All analyses were carried out with STATA version 12.0
(StataCorp, College Station, TX). All tests were two sided,
and a p value < 0.05 was considered statistically significant.
Results
Among 1154 patients who underwent liver resection for ICC,
overall actuarial survival at 5 and 10 years was 39.6 and
20.3%, respectively (Fig. 1). In the entire cohort, the incidence
of actual survivors was 13.3% (n = 153) at 5 years, and among
these patients, the incidence of actual survivors at 10 years
was 10.4% (n = 16). Excluding 475 patients who were alive
with a follow-up < 5 years, the analytic cohort consisted of
153 patients (22.5%) in the long-term survival group (LT) vs.
526 patients (77.5%) who died within 5 years of surgery in the
non-long-term survival group (non-LT).
Many clinical and demographic factors among LTand non-
LT patients were comparable (Table 1). For example, the pro-
portion of men (non-LT, n = 788, 51.0% vs. LT, n = 306,
58.3%), median age (non-LT, 60 years, IQR, 45–69 vs. LT,
59 years, IQR, 49–66), as well as the incidence of cirrhosis
(non-LT, n = 62, 14.5% vs. LT, n = 17, 14.2%), HBV (non-LT,
n = 90, 21.5% vs. LT, n = 30, 25.6%), and HCV (non-LT,
n = 16, 3.9% vs. LT, n = 5, 4.3%) were similar (all
p > 0.05). In addition, utilization of preoperative chemothera-
py was the same among non-LT (n = 7, 6.3%) and LT (n = 34,
8.9%) patients (p = 0.37). The use of adjuvant chemotherapy
and radiotherapy also did not differ among non-LT and LT
patients (adjuvant chemotherapy: non-LT group, n = 165,
33.3% vs. LT group, n = 52, 34.7%, p = 0.75) (adjuvant
radiotherapy: non-LT: n = 30, 7.4% vs. LT, n = 7, 5.5%,
p = 0.46).
A number of prognostic factors were, however, different
among non-LT vs. LT patients. In particular, the incidence of
periductal infiltrating/mass forming + periductal infiltrating
(PI/MF + PI) tumor morphology and R1 surgical margin sta-
tus was lower among LT patients compared with non-LT pa-
tients (PI/MF + PI: non-LT: n = 89, 17.9% vs. LT, n = 11,
7.1%, p = 0.002) (R1: non-LT, n = 83, 15.9% vs. LT, n = 11,
7.2%, p = 0.006). Moreover, the incidence of N1 disease and
tumor size > 5 cm was also lower in the LT vs. non-LT group
(N1: non-LT group, n = 123, 23.4% vs. LT group, n = 9, 5.9%,
p < 0.001) (tumor size > 5 cm: non-LT group, n = 361, 68.6%
vs. LT group, n = 75, 49.1%, p < 0.001). ICC involvement of
adjacent organs was present in 48 (12.9%) non-LT patients
compared with 3 (2.2%) LT patients (p = 0.003). In addition,
the incidence of microvascular (microvascular invasion: non-
LT group, n = 171, 33.3% vs. LT group, n = 34, 22.2%,
p = 0.009) and perineural invasion (perineural invasion:
non-LT group, n = 111, 23.2% vs. LT group, n = 12, 8.8%,
p < 0.001) (Fig. 2a) were lower in the LT group. Median
values of CA 19-9 and CEAwere also lower in the LT group
than in the non-LT group (CA 19-9: non-LT group, 84.2, IQR,
Fig. 1 Kaplan-Meier estimates of overall survival among the 1154
patients undergoing liver resection with curative intent for intrahepatic
cholangiocarcinoma
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Table 1 Clinical and pathologic
features of patients (n = 679) Non-LT N (%) LT N (%) p value
Patients 526 (77.5%) 153 (22.5%) –
Age, median (IQR) 60 years (45–69) 59 years (49–66) 0.40
Gender 0.11
Female 219 (41.7%) 75 (49.0%)
Male 307 (58.3%) 78 (51.0%)
Cirrhosis 0.93
No 366 (85.5%) 103 (85.8%)
Yes 62 (14.5%) 17 (14.2%)
NA 98 33
HBV infection 0.35
No 328 (78.5%) 87 (74.4%)
Yes 90 (21.5%) 30 (25.6%)
NA 108 36
HCV infection 0.85
No 393 (96.1%) 111 (95.7%)
Yes 16 (3.9%) 5 (4.3%)
NA 117 37
Neoadjuvant chemotherapy 0.37
No 347 (91.1%) 105 (93.7%)
Yes 34 (8.9%) 7 (6.3%)
NA 145 41
Morphological type 0.002
MF, IG 408 (82.1%) 132 (92.9%)
PI, MF + PI 89 (17.9%) 10 (7.1%)
NA 29 11
Margin status 0.006
R0 437 (84.0%) 142 (92.8%)
R1 83 (15.9%) 11 (7.2%)
NA 6 –
Lymph node status < 0.001
N0 119 (22.6%) 45 (29.4%)
N1 123 (23.4%) 9 (5.9%)
NX 284 (54.0%) 99 (64.7%)
Tumor size < 0.001
≤ 5 cm 165 (31.4%) 78 (50.9%)
> 5 cm 361 (68.6%) 75 (49.1%)
Liver capsule involvement 0.88
No 419 (79.7%) 121 (79.1%)
Yes 107 (20.3%) 32 (20.9%)
Direct invasion adjacent organs 0.003
No 478 (89.6%) 150 (98.0%)
Yes 48 (10.4%) 3 (2.0%)
Major vascular resection 0.55
No 458 (87.1%) 136 (88.9%)
Yes 68 (12.9%) 17 (11.1%)
Bile duct resection < 0.001
No 358 (77.5%) 123 (91.8%)
Yes 104 (22.5%) 11 (8.2%)
NA 64 19
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23.7–400.0 vs. LT group, 25.5, IQR, 11.0–107.8, p < 0.001;
CEA: non-LT group, 2.8, IQR, 1.6–5.4 vs. LT group, 1.8,
IQR, 1.0–3.2, p < 0.001). More patients in the non-LT group
had a poorly/undifferentiated tumor (n = 114, 23.3%) com-
pared with LT patients (n = 18, 12.8%, p = 0.007; Table 1).
After controlling for competing risk factors on multivari-
able analysis, several factors remained strongly associated
with LT (Table 2). For example, patients with direct invasion
of adjacent organs had an almost fourfold decreased odds of
surviving to 5 years compared with patients without direct
invasion of adjacent organs (OR 3.98, 95% CI, 1.18–13.4,
p = 0.026) (Fig. 2b). Patients with intrahepatic metastasis
(OR 3.75, 95% CI, 0.85–16.6, p = 0.082) (Fig. 2c) and satel-
lite lesions (OR 2.12, 95% CI, 1.15–3.90, p = 0.016) (Fig. 2d)
were also less likely to be LT survivors. Patients with an ICC
> 5 cm had an increased risk to be in the non-LT group than in
the LT group (OR 2.40, 95% CI, 1.54–3.74, p < 0.001)
(Fig. 2e). Accordingly, in the Kaplan-Meier analysis, 5- and
10-year OS was 32 and 16%, respectively, for patients with
ICC ≥ 5 cm vs. 52 and 27% for patients with an ICC < 5 cm.
Of note, N1 status (OR 4.64, 95% CI, 1.77–12.2; p = 0.002)
and perineural invasion (OR 4.78, 95% CI, 1.92–11.8;
p = 0.001) were the strongest independent predictors of poor
prognosis and decreased likelihood of LT. In the LT group,
while only three (2.0%) patients had intrahepatic metastasis
and direct invasion of adjacent organs, 5% of patients in the
LT group had satellite lesion (n = 18, 11.8%), perineural inva-
sion (n = 12, 8.8%), N1 status (n = 9, 5.9%), and ICC ≥ 5 cm
(n = 75, 49.1%).
In comparing LT vs. non-LT patients, the AJCC 8th edition
T1b, T2, and T4 patients were under-represented in LT group
vs. non-LT group (T1b: non-LT group, n = 129, 80.1% vs. LT
group, n = 32, 19.9%; T2: non-LT group, n = 205, 84.4% vs.
LT group, n = 38, 15.6%; T4: non-LT group, n = 48, 94.1% vs.
Table 1 (continued)
Non-LT N (%) LT N (%) p value
Grade 0.007
Well/moderate 377 (76.8%) 123 (87.2%)
Poorly/undifferentiated 114 (23.2%) 18 (12.8%)
NA 35 12
Microvascular invasion 0.009
No 342 (66.7%) 119 (77.8%)
Yes 171 (33.3%) 34 (22.2%)
NA 13 –
Perineural invasion < 0.001
No 368 (76.8%) 125 (91.2%)
Yes 111 (23.2%) 12 (8.8%)
NA 47 16
Satellite lesion < 0.001
No 370 (70.9%) 135 (88.2%)
Yes 152 (29.1%) 18 (11.8%)
NA 4 –
Intrahepatic metastasis 0.002
No 474 (90.6%) 150 (98.0%)
Yes 49 (9.4%) 3 (2.0%)
NA 3 –
Ca 19–9, median (IQR) 84.2 (23.7–400.0) 25.5 (11.0–107.8) < 0.001
CEA, median (IQR) 2.8 (1.6–5.4) 1.8 (1.0–3.2) < 0.001
Adjuvant chemotherapy 0.75
No 331 (66.7%) 98 (65.3%)
Yes 165 (33.3%) 52 (34.7%)
NA 30 3
Adjuvant radiotherapy 0.46
No 378 (92.6%) 121 (94.5%)
Yes 30 (7.4%) 7 (5.5%)
NA 118 25
NA not available
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LT group, n = 3, 5.9%) (all p < 0.05). In contrast, more LT
patients were noted to be AJCC T1a and T3 than in T1b
and T2 (T1a: non-LT group, n = 71, 58.2% vs. LT group,
n = 51, 41.8%; T3: non-LT group, n = 73, 71.6% vs. LT
group, n = 29, 28.4%, p < 0.001) (Table 3). When nodal
status was restricted to patients who had at least six LNs
harvested as recommended by the AJCC, the proportion
of LT survivors who were N0 or NX was 31% (n = 16)
and 25.8% (n = 128), respectively, whereas only a mi-
nority of LT patients were N1 (n = 9, 6.8%) (Table 3).
Only 158 (30.0% of 526 patients in the non-LT group)
and 25 (16.3% of 153 patients in the LT group) patients
in non-LT and LT groups, respectively, had an adequate
nodal staging and were staged according to the AJCC
8th edition TNM staging system. The incidence of LT
was 80% in stage Ia, 25% in stage Ib, 35% in stage II,
12% in stage III, and 7% in stage IV. In contrast, the
incidence of non-LT was 93% in stage IIIb and decreased
to only 20% in stage Ia (Table 3).
Fig. 2 Histogram showing the
incidence of patients stratified by
a perineural invasion, b invasion
of adjacent organs, c intrahepatic
metastasis, d satellite lesions, and
e tumor size in the long-term vs.
non-long-term groups
Table 2 Multivariable analysis
OR 95% CI p value
Intrahepatic metastasis 3.75 0.85–16.6 0.082
Direct invasion adjacent organs 3.98 1.18–13.4 0.026
Perineural invasion 4.78 1.92–11.8 0.001
Satellite lesion 2.12 1.15–3.90 0.016
Lymphnode status
N0 – – –
N1 4.64 1.77–12.2 0.002
NX 1.28 0.76–2.15 0.36
Size > 5 cm 2.40 1.54–3.74 < 0.001
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Discussion
Although complete surgical resection remains the treatment
of choice for patients with ICC, the prognosis of ICC re-
mains unfavorable with 5-year survival ranging from 20 to
40%.23 Several studies have identified clinicopathological
factors associated with long-term outcomes of patients un-
dergoing liver surgery for ICC, such as preoperative CA 19-
9 levels, tumor number and size, lymph node status, margin
status, as well as vascular invasion.2, 13, 16, 24–30 Several
predictive models have been applied to patients with ICC
in order to better define prognosis.9, 26, 31 The most com-
monly used staging system for ICC is the TNM classifica-
tion system. In the recently released new 8th edition of the
AJCC TNM manual, several new revisions were introduced
into the staging for ICC.8 Specifically, in the 8th edition, T1
disease has been revised to include tumor size (≤ 5 cm vs. >
5 cm); T2 now reflects an equivalent prognostic value of
vascular invasion and multifocal disease; while T4 disease
is defined as involving local extrahepatic structures by direct
invasion. Hyder et al. reported a prognostic nomogram for
resectable ICC based on the clinicopathologic data of 367
patients with ICC that included six factors, such as age,
tumor size, number of lesions, nodal status, vascular inva-
sion, and presence of cirrhosis.9 Most of these past studies
focused, however, on short-term prognosis within 5 years of
surgery. To our knowledge, no past studies has specifically
focused on the actual long-term survivors following
curative-intent resection of ICC to identify clinicopathologi-
cal factors associated with long-term survival. The current
study is important because it is one of the first studies to
examine the incidence of actual long-term survivors in a
large, multi-center cohort of over 1000 patients undergoing
surgery for ICC at 1 of 14 major hepatobiliary centers in the
USA, Europe, Australia, and Asia, as well as measure the
impact of clinicopathological factors on long-term survivors.
When analyzing the data, it was interesting to note that
analysis of actual survivors provided additional information
compared with simple, standard Kaplan-Meier survival esti-
mates. In particular, while the calculated actuarial OS at
5 years was roughly 40%, there were only 153 (13%) actual
long-term survivors among the 1154 patients following
curative-intent surgery. In turn, data from the current study
provide more accurate Bactual^ data on the long-term prog-
nosis of patients undergoing curative intent surgery of ICC.
While Kaplan-Meier analyses are helpful in estimating prog-
nosis, this type of survival analysis may underestimate the
effect of patients lost to follow-up and who are therefore
censored in the analysis. Lost to follow-up may be particu-
larly important among patients with ICC given the high risk
of recurrence and death of disease in the first years follow-
ing surgery for ICC.32 As such, patients lost to follow-up
are likely to adversely impact any estimation of prognosis
and the Kaplan-Meier method may overestimate true
survival.14, 33 In turn, some groups, like our own, have
proposed using nonmixture cure models as a means to bet-
ter estimate the chance of statistical cure following surgical
resection.15, 34, 35 In fact, using a noncore statistical model,
we had previously estimated that the overall probability of
cure was approximately 10% for Ball comer^ patients un-
dergoing hepatic resection for ICC. Interestingly, data from
our previous statistical model (10%) very closely approxi-
mated the 13% incidence of actual long-term survivors re-
ported in the current study.
Table 3 Long-term survivors
and AJCC staging system 8th
edition
Non-LT N (%) LT N (%) p value OR 95% IC p value
AJCC T stages < 0.001
T1a 71 (58.2%) 51 (41.8%) – – –
T1b 129 (80.1%) 32 (19.9%) 2.89 1.71–4.91 < 0.001
T2 205 (84.4%) 38 (15.6%) 3.87 2.35–6.38 < 0.001
T3 73 (71.6%) 29 (28.4%) 1.81 1.03–3.17 0.038
T4 48 (94.1%) 3 (5.9%) 11.5 3.39–38.9 < 0.001
AJCC N stages < 0.001
N0 35 (68.6%) 16 (31.4%) – – –
N1 123 (93.2%) 9 (6.8%) 6.25 2.54–15.3 < 0.001
NX 368 (74.2%) 128 (25.8%) 1.31 0.70–2.45 0.39
AJCC TNM stages < 0.001
Ia 1 (16.7%) 5 (83.3%) – – –
Ib 8 (72.7%) 3 (27.3%) 12.0 0.79–180.9 0.07
II 17 (70.8%) 7 (29.2%) 7.42 0.69–79.9 0.09
IIIa 9 (90.0%) 1 (10.0%) 28.0 1.35–580.6 0.031
IIIb 123 (93.2%) 9 (6.8%) 54.7 5.51–541.7 0.001
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Perhaps not surprisingly, LT patients had manymore favor-
able prognostic factors compared with non-LT patients. In
particular, patients who were in the LT group had a lower
incidence of PI/MF + PI ICC vs. the non-LT group
(p = 0.002). As our group recently reported, PI/MF + PI tu-
mors were associated with more aggressive features than MF/
IG ICC.36 Specifically, patients with a PI/MF + PI tumor had a
5-year OS of 25.5% vs. 41.8% for patients with a MF/IG ICC
(p < 0.001). Also, the incidence of tumors ≥ 5 cmwas lower in
the LT group, with over a twofold increased odds that patients
with an ICC ≥ 5 cm were in the non-LT group (OR 2.40;
p < 0.001). The correlation between tumor size and long-
term outcome has been previously evaluated.24 Hyder et al.
reported that tumor size was a prognostic factor for survival
after surgical resection for ICC and noted that the association
of tumor size on survival plateaued at 7 cm.9 The effect of
tumor size on outcome has been correlated to the underlying
presence of microscopic vascular invasion and higher tumor
grade in larger ICC.13 In a study by Spolverato et al., one third
and one half of patients with tumors measuring 7 to 15 and ≥
15 cm, respectively, had microscopic vascular invasion and
one in three patients with tumors ≥ 15 cm had evidence of
major vascular invasion.13 Consistent with these previous
findings, patients in the LT group were more likely to have
well/moderately differentiated ICC and to have tumors with
microvascular invasion. The importance of N status has also
been reported in previous studies.7, 10, 11, 37–44 In a recent
meta-analysis, LN metastasis was associated with increased
risk of death in pool data (HR 2.09),7 and Kim et al. confirmed
these findings reporting a similar relative risk of death associ-
ated with LNmetastasis (HR 2.42; p < 0.001).12 In the current
study, lymph node metastasis (OR 4.64; p = 0.002) was one of
the strongest independent predictors of poor prognosis and
decreased chance of long-term survival. In fact, when the
AJCC recommended cut-off of six LNs harvested was applied
to identify N0 patients, the incidence of LTs in N0 stage in-
creased to 31%, which was higher than the incidence of LTs in
either the N1 and NX categories. Collectively, these data serve
to emphasize both the prognostic value of N status and the
importance of adequate nodal staging.
LT patients were more likely to have T1a-T1b-T3 tumors
(i.e., solitary tumor measuring ≤ 5 cm (T1a); solitary tumor >
5 cm (T1b); tumor perforating the visceral peritoneum (T3)),
rather than T2 tumors (i.e., solitary tumor with intrahepatic
vascular invasion or multiple tumors, with or without vascular
invasion). These data suggest that perforation of the visceral
peritoneum may not carry as poor a prognostic impact as
vascular invasion. In fact, Spolverato et al. previously reported
that, while T1b patients had a better 5-year OS (37.3%) than
T2 patients (21.3%), T3 patients paradoxically had a better 5-
year OS than either of these lower T categories (45.8%).18 As
such, an advanced T stage tumor may not preclude long-term
survival. Moreover, while stage T2 includes both patients with
intrahepatic metastases (multiple lesions in different seg-
ments) and satellite lesions (dominant mass with nodules in
same segment), in the current analyses, these two distinct pat-
terns of multifocal disease were associated with different
chances of LT survival (intrahepatic metastasis: OR 3.75; sat-
ellite lesions: OR 2.12). Based on these results, stages T2 and
T3 might need to be redefined to better stratify patient
prognosis.
Another interesting finding of the current study was that
traditional adverse prognostic factors did not categorically
preclude LT survival. To this point, a subset of patients in
the LT survival group were characterized by a number of tra-
ditionally poor prognostic factors including R1 disease (7%),
T3 tumors (19%), moderate/poor tumor differentiation (13%),
and N1 disease (6%). These data emphasize how prognostic
factors cannot be utilized to rule out the possibility of LT
survival even in patients with predicted poor outcomes. To
this end, several groups have reported on using conditional
survival estimates to provide quantitative information about
the changing probability of survival over time among patients
with cancer.34, 35, 45, 46 Spolverato and colleagues reported
that, while actuarial OS decreased over time from 39% at
3 years to 16% at 8 years, 3-year conditional increased over
time among those patients who survived.15 In fact, the 3-year
conditional survival at 5 years—the probability of surviving to
postoperative year 8 after having already survived to postop-
erative year 5—was 65% compared with an 8-year actuarial
OS estimate of 16%. Taken together, while certain factors may
be strongly associated with LT survival, data in the current
study, as well as previous data, demonstrate that LT can occur
even in a subset of patients with traditional adverse prognostic
factors.
The current study had several limitations. The multi-center
nature of the study also did not allow for standardization of
operative or perioperative approach, especially in terms of
performance and extent of lymphadenectomy, neoadjuvant
and adjuvant chemotherapy, and follow-up. Although this is
a possible limitation, it is also a strength of the study as it
contributes to the generalizability of the data. Due to the ret-
rospective nature of the study, selection bias should be taken
into account when interpreting the results; however, such con-
founding was unlikely to impact the evaluation of the prog-
nostic features of long-term survivors.
In conclusion, while ICC is generally associated with a
poor prognosis, some patients can survive more than 5 years
after surgery. The incidence of LT survivors following
curative-intent surgery was low, as only one in ten patients
actually survived past 5 years. Several pathological factors
were associated with the likelihood of LT survivorship, yet
LT survival did occur among a small subset of patients who
had poor prognostic features. ICC is an aggressive disease
with few LT survivors even after curative-intent surgery.
Efforts should be aimed to better understand the pathogenesis
J Gastrointest Surg (2017) 21:1888–1897 1895
and molecular underpinnings of ICC in order to identify more
effective systemic therapeutic agents. Only through the dis-
covery and implementation of novel therapeutic approaches
will we be able to improve the LT outcomes of patients with
ICC.
References
1. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L,
Amaratunge HC et al. Risk of hepatobiliary and pancreatic cancers
after hepatitis C virus infection: a population-based study of U.S.
veterans. Hepatology. 2009;49(1):116–23. https://doi.org/10.1002/
hep.22606.
2. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D et al.
Intrahepatic cholangiocarcinoma: rising frequency, improved sur-
vival, and determinants of outcome after resection. Annals of
Surgery. 2008; 248(1):84–96. https://doi.org/10.1097/SLA.
0b013e318176c4d3.
3. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in un-
derstanding a deadly old disease. Journal of Hepatology. 2006;
45(6):856–67. https://doi.org/10.1016/j.jhep.2006.09.001.
4. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence
of intrahepatic cholangiocarcinoma in the United States: a true in-
crease? Journal of Hepatology. 2004; 40(3):472–7. https://doi.org/
10.1016/j.jhep.2003.11.030.
5. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM.
Impact of classification of hilar cholangiocarcinomas (Klatskin tu-
mors) on the incidence of intra- and extrahepatic cholangiocarcino-
ma in the United States. Journal of the National Cancer Institute.
2006; 98(12):873–5. https://doi.org/10.1093/jnci/djj234.
6. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk
factors, and pathogenesis of cholangiocarcinoma. HPB: the Official
Journal of the International Hepato Pancreato Biliary Association.
2008; 10(2):77–82. https://doi.org/10.1080/13651820801992641.
7. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM.
Treatment and prognosis for patients with intrahepatic cholangio-
carcinoma: systematic review and meta-analysis. JAMA Surgery.
2014. https://doi.org/10.1001/jamasurg.2013.5137.
8. Amin MB EiC, American Joint Committee on Cancer. Springer.
2017.
9. Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S,
Bauer TW et al. A nomogram to predict long-term survival after
resection for intrahepatic cholangiocarcinoma: an Eastern and
Western experience. JAMA Surgery. 2014. https://doi.org/10.
1001/jamasurg.2013.5168.
10. Amini N, Ejaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM.
Management of lymph nodes during resection of hepatocellular
carcinoma and intrahepatic cholangiocarcinoma: a systematic re-
view. Journal of Gastrointestinal Surgery: Official Journal of the
Society for Surgery of the Alimentary Tract. 2014; 18(12):2136–
48. https://doi.org/10.1007/s11605-014-2667-1.
11. Bagante F, Gani F, Spolverato G, Xu L, Alexandrescu S, Marques
HP et al. Intrahepatic cholangiocarcinoma: prognosis of patients
who did not undergo lymphadenectomy. Journal of the American
College of Surgeons. 2015; 221(6):1031–40 e4. https://doi.org/10.
1016/j.jamcollsurg.2015.09.012.
12. Kim Y, Spolverato G, Amini N, Margonis GA, Gupta R, Ejaz A
et al. Surgical Management of intrahepatic cholangiocarcinoma:
defining an optimal prognostic lymph node stratification schema.
Annals of Surgical Oncology. 2015; 22(8):2772–8. https://doi.org/
10.1245/s10434-015-4419-1.
13. Spolverato G, Ejaz A, Kim Y, Sotiropoulos GC, Pau A,
Alexandrescu S et al. Tumor size predicts vascular invasion and
histologic grade among patients undergoing resection of
intrahepatic cholangiocarcinoma. Journal of Gastrointestinal
Surgery: Official Journal of the Society for Surgery of the
Alimentary Tract. 2014; 18(7):1284–91. https://doi.org/10.1007/
s11605-014-2533-1.
14. Spolverato G, Kim Y, Ejaz A, Alexandrescu S, Marques H,
Aldrighetti L et al. Conditional probability of long-term survival
after liver resection for intrahepatic cholangiocarcinoma: a multi-
institutional analysis of 535 patients. JAMA Surgery. 2015; 150(6):
538–45. https://doi.org/10.1001/jamasurg.2015.0219.
15. Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP,
Aldrighetti L et al. Can hepatic resection provide a long-term cure
for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;
121(22):3998–4006. https://doi.org/10.1002/cncr.29619.
16. Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP,
Lamelas J et al. The impact of surgical margin status on long-term
outcome after resection for intrahepatic cholangiocarcinoma.
Annals of Surgical Oncology. 2015. https://doi.org/10.1245/
s10434-015-4472-9.
17. Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP,
Lamelas J et al. Impact of complications on long-term survival after
resection of intrahepatic cholangiocarcinoma. Cancer. 2015;
121(16):2730–9. https://doi.org/10.1002/cncr.29419.
18. Spolverato G BF, Weiss, M, Alexandrescu S, Marques HP,
Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F,
Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi
A, Itaru E, Pawlik TM. Comparative performances of the 7th and
the 8th editions of the American Joint Committee on Cancer
Staging Systems for intrahepatic cholangiocarcinoma. Journal of
Surgical Oncology.
19. Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholan-
giocarcinoma. Hepatobiliary Surg Nutr. 2017; 6(1):35–43. https://
doi.org/10.21037/hbsn.2016.10.02.
20. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S
et al. Pancreatic adenocarcinoma: the actual 5-year survivors.
Journal of Gastrointestinal Surgery: Official Journal of the Society
for Surgery of the Alimentary Tract. 2008; 12(4):701–6. https://doi.
org/10.1007/s11605-007-0384-8.
21. Zheng J, Kuk D, Gonen M, Balachandran VP, Kingham TP, Allen
PJ et al. Actual 10-year survivors after resection of hepatocellular
carcinoma. Annals of Surgical Oncology. 2017; 24(5):1358–66.
https://doi.org/10.1245/s10434-016-5713-2.
22. Baheti AD, Tirumani SH, Shinagare AB, Rosenthal MH, Hornick
JL, Ramaiya NH et al. Correlation of CT patterns of primary
intrahepatic cholangiocarcinoma at the time of presentation with
the metastatic spread and clinical outcomes: retrospective study of
92 patients. Abdominal Imaging. 2014; 39(6):1193–201. https://
doi.org/10.1007/s00261-014-0167-0.
23. De JongMC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S,
Marques H et al. Intrahepatic cholangiocarcinoma: an international
multi-institutional analysis of prognostic factors and lymph node
assessment. Journal of Clinical Oncology: Official Journal of the
American Society of Clinical Oncology. 2011; 29(23):3140–5.
https://doi.org/10.1200/jco.2011.35.6519.
24. Dodson RM,Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders
R et al. Intrahepatic cholangiocarcinoma: management options and
emerging therapies. Journal of the American College of Surgeons.
2013; 217(4):736–50e4. https://doi.org/10.1016/j.jamcollsurg.
2013.05.021.
25. de JongMC, Pulitano C, Ribero D, Strub J,Mentha G, Schulick RD
et al. Rates and patterns of recurrence following curative intent
surgery for colorectal liver metastasis: an international multi-
institutional analysis of 1669 patients. Annals of Surgery. 2009;
250(3):440–8. https://doi.org/10.1097/SLA.0b013e3181b4539b.
1896 J Gastrointest Surg (2017) 21:1888–1897
26. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick
RD et al. A proposed staging system for intrahepatic cholangiocar-
cinoma. Annals of Surgical Oncology. 2009; 16(1):14–22. https://
doi.org/10.1245/s10434-008-0180-z.
27. Spolverato G, Kim Y, Alexandrescu S, Popescu I, Marques HP,
Aldrighetti L et al. Is hepatic resection for large or multifocal
intrahepatic cholangiocarcinoma justified? Results from a multi-
institutional collaboration. Annals of Surgical Oncology. 2014.
https://doi.org/10.1245/s10434-014-4223-3.
28. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F,
Winter JM, Lillemoe KD et al. Cholangiocarcinoma: thirty-one-
year experience with 564 patients at a single institution. Annals of
Surgery. 2007; 245(5):755–62. https://doi.org/10.1097/01.sla.
0000251366.62632.d3.
29. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N.
Surgical outcome and prognostic factors in intrahepatic cholangio-
carcinoma. World Journal of Surgery. 2008; 32(12):2675–80.
https://doi.org/10.1007/s00268-008-9778-3.
30. Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC,
Bloomston M. Elevated CA 19-9 portends poor prognosis in pa-
tients undergoing resection of biliary malignancies. HPB: the
Official Journal of the International Hepato Pancreato Biliary
Association. 2010; 12(2):134–8. https://doi.org/10.1111/j.1477-
2574.2009.00149.x.
31. Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarcinoma.
Current Opinion in Gastroenterology. 2010; 26(3):269–73. https://
doi.org/10.1097/MOG.0b013e328337c899.
32. Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S,
Marques H et al. Recurrence after operative management of
intrahepatic cholangiocarcinoma. Surgery. 2013; 153(6):811–8.
https://doi.org/10.1016/j.surg.2012.12.005.
33. Bollschweiler E. Benefits and limitations of Kaplan-Meier calcula-
tions of survival chance in cancer surgery. Langenbeck’s Archives
of Surgery/Deutsche Gesellschaft fur Chirurgie. 2003; 388(4):239–
44. https://doi.org/10.1007/s00423-003-0410-6.
34. Bagante F, Spolverato G,Merath K, Postlewait LM, Poultsides GA,
Mullen MG et al. Neuroendocrine liver metastasis: the chance to be
cured after liver surgery. J Surg Oncol. 2017. https://doi.org/10.
1002/jso.24563.
35. Spolverato G, Bagante F, Ethun CG, Poultsides G, Tran T, Idrees K
et al. Defining the chance of statistical cure among patients with
extrahepatic biliary tract cancer. World J Surg. 2017; 41(1):224–31.
https://doi.org/10.1007/s00268-016-3691-y.
36. Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP,
Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F,
Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi
A, Itaru E, Pawlik TM. Impact of morphological status on long-
term outcome among patients undergoing liver surgery for
intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017; 24:
2491–2501.
37. Adachi T, Eguchi S. Lymph node dissection for intrahepatic chol-
angiocarcinoma: a critical review of the literature to date. Journal of
Hepato-Biliary-Pancreatic Sciences. 2014; 21(3):162–8. https://doi.
org/10.1002/jhbp.30.
38. Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM
et al. Surgical approach for long-term survival of patients with
intrahepatic cholangiocarcinoma: a multi-institutional analysis of
434 patients. Archives of Surgery. 2012; 147(12):1107–13.
39. Ercolani G, Vetrone G, Grazi GL, Aramaki O, Cescon M, Ravaioli
M et al. Intrahepatic cholangiocarcinoma: primary liver resection
and aggressive multimodal treatment of recurrence significantly
prolong survival. Annals of Surgery. 2010; 252(1):107–14.
https://doi.org/10.1097/SLA.0b013e3181e462e6.
40. Saxena A, Chua T, Sarkar A, Chu F, Morris D. Clinicopathologic
and treatment-related factors influencing recurrence and survival
after hepatic resection of intrahepatic cholangiocarcinoma: a 19-
year experience from an established Australian Hepatobiliary
Unit. Journal of Gastrointestinal Surgery. 2010; 14(7):1128–38.
https://doi.org/10.1007/s11605-010-1203-1.
41. Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S,
Valdegamberi A, Nicoli P et al. Intrahepatic cholangiocarcinoma:
prognostic factors after surgical resection. World Journal of
Surgery. 2009; 33(6):1247–54. https://doi.org/10.1007/s00268-
009-9970-0.
42. Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W,
Schonleben F. Surgical treatment of mass-forming intrahepatic
cholangiocarcinoma: an 11-year western single-center experience
in 107 patients. Annals of Surgical Oncology. 2009; 16(2):404–12.
43. Uenishi T, Kubo S, Yamazaki O, Yamada T, Sasaki Y, Nagano H
et al. Indications for surgical treatment of intrahepatic cholangiocar-
cinoma with lymph node metastases. Journal of Hepato-Biliary-
Pancreatic Surgery. 2008; 15(4):417–22. https://doi.org/10.1007/
s00534-007-1315-5.
44. Yamashita Y, Taketomi A, Morita K, Fukuhara T, Ueda S, Sanefuji
K et al. The impact of surgical treatment and poor prognostic factors
for patients with intrahepatic cholangiocarcinoma: retrospective
analysis of 60 patients. Anticancer Research. 2008; 28(4C):2353–9.
45. Rama R, Swaminathan R, Venkatesan P. Cure models for estimat-
ing hospital-based breast cancer survival. Asian Pac J Cancer Prev.
2010; 11(2):387–91.
46. Rasouli M, Ghadimi MR, Mahmoodi M,Mohammad K, Zeraati H,
Hosseini M. Survival analysis of patients with esophageal cancer
using parametric cure model. Asian Pac J Cancer Prev. 2011; 12(9):
2359–63.
J Gastrointest Surg (2017) 21:1888–1897 1897
